Just reported
From Regeneron Pharmaceuticals's results release of 30 de outubro de 2026; its quarterly report has since been filed.
Actual
US$ 5,12B
+36% y/y
+19% q/q
Guided
—
No guide given
Actual
US$ 18,45
+35% y/y
+51% q/q
Guided
—
No guide given
Actual
US$ 2,05B
+99% y/y
+58% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →As participações na receita são estimativas para quarter ended March 31, 2026, não números de um relatório oficial.
Dupixent
An injected medicine used for several allergic and inflammatory conditions, including eczema, asthma, and chronic obstructive pulmonary disease.
EYLEA HD
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
EYLEA
An injection into the eye for retinal diseases, including wet age-related macular degeneration and diabetic macular edema.
Libtayo
An immune-system cancer medicine used for several cancers, including certain skin cancers and lung cancer.
Praluent
An injected medicine that lowers cholesterol and reduces cardiovascular risk in some patients.
Otarmeni
A gene therapy for hearing loss caused by changes in the otoferlin gene.
Demonstrações financeiras completas →
Regeneron discovers, develops, makes, and sells medicines for conditions including eye diseases, allergic and inflammatory diseases, and cancer. Its medicines include Dupixent for inflammatory diseases, EYLEA for retinal conditions, and Libtayo for cancer. It sells some medicines itself and shares sales profits with partners such as Sanofi and Bayer, which also sell certain medicines.
Construído a partir dos próprios documentos de Regeneron Pharmaceuticals, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
The themes Regeneron Pharmaceuticals is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$ 951,74-0,8%fechamento 12 de nov.
Números até 30 de setembro de 2026, do 10-Q arquivado em 30 de outubro de 2026
Regeneron develops prescription medicines, led by Dupixent for allergic and inflammatory diseases, and sells them to drug distributors, pharmacies, hospitals, and health agencies.
Grade C+
A faixa sob o preço mostra a nota em cada data, calculada só com os documentos já públicos naquele momento.
Mostrando 2 de 41 trimestres do histórico de notas de Regeneron Pharmaceuticals, Inc.. Os outros 39 vão até novembro de 2016.
